Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

re: Contracts

7 Apr 2005 07:00

Marchpole Holdings PLC07 April 2005 07 April 2005 Marchpole Holdings plc ("the Company") MARCHPOLE CONTINUES TO EXPAND CASTELBAJAC Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ('JCC'), Rossignol, Emanuel Ungaro and Ungaro), ispleased to announce that three significant contracts for their Jean Charles deCastelbajac ("JCC") business have been agreed. Extended Agreement with Itochu for Japan The Company is pleased to announce that its design agreement with Itochu hasbeen extended for a further six years from 2005 to 2011. Itochu manufacture, wholesale and retail Castelbajac collections for theJapanese market place with sales at wholesale prices for 2004 over €25 million.As part of this new agreement the design fee on these sales will be increasedfrom the current rate of 1.7% to 2.5% from October 2005. Sales for 2005 areexpected to reach €30 million. Castelbajac and Rossignol Launch New Collection Jean Charles de Castelbajac designed and launched his first Skiwear collectionfor the Autumn Winter 2002 season in collaboration with the world's number oneskiwear brand Rossignol. Over the course of the last two years sales haveincreased from €0.5 million to €3.2 million for Autumn Winter 2004 and sales forAutumn Winter 2005 are forecast to be €3.7 million. This is the fastest growingbusiness line within the Rossignol group. Following this success, Rossignol have asked Jean Charles to design and launch anew collection for the Summer. This new collection is aimed at the TrekkingOutdoor market. Launching in the Spring Summer 2006 season, the new agreement is for 5 years,with minimum guaranteed royalties over the period totalling €325,000. Castelbajac Glasses and Sunglasses The company has also signed an agreement with Codir SA to launch Castelbajaceyewear across Europe. Codir SA are the leader in market share with more than2700 retail outlets and sales of over €700 million. The contract is for 3 years, launching in Spring Summer 2005 with minimumguaranteed royalties for the period of €230,000. Commenting today, Chief Executive Greg Tufnell said : "Marchpole acquired the Castelbajac business in 2004 with the aim of creating astrong worldwide brand under its ownership. These new contracts, and thesignificant marketing contribution from the licensees, clearly demonstrate ourability to transform and grow this brand. We are successfully increasing ourpresence across a wide assortment of product categories and establishing thebrand in both Asia and Europe" For further information contact: Marchpole Greg Tufnell - Chief Executive 020 7908 7700 Michael Morris - Executive Director Shore Capital Alex Borrelli 020 7408 4090 Buchanan Tim Thompson / Nicola Cronk 020 7466 5000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th May 20177:00 amRNSInitiation of BPS-804 Phase 2b study
28th Apr 20173:37 pmRNSHolding(s) in Company
28th Apr 201712:53 pmRNSHolding(s) in Company
28th Apr 201710:05 amRNSHolding(s) in Company
26th Apr 20177:00 amRNSConversion of loan note and issue of equity
24th Apr 20176:07 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSGrant of Options and Awards
3rd Apr 20177:00 amRNSResults of Placing
31st Mar 20175:54 pmRNSResults of Placing
29th Mar 201712:30 pmRNSProposed Placing
15th Mar 20177:00 amRNSPosting of Annual Report and Notice of AGM
7th Mar 20177:00 amRNSPositive recommendation for BGS-649 Phase 2b trial
27th Feb 20177:00 amRNSPreliminary Results
20th Feb 20177:00 amRNSEMA Adaptive Pathways programme accepts BPS-804
23rd Jan 20177:05 amRNSPresentation at Shares Spotlight Evening
23rd Jan 20177:00 amRNSThree abstracts accepted for ATS Meeting
12th Jan 20177:01 amRNSDirectorate update
5th Jan 201712:00 pmRNSMereo BioPharma to Present at Biotech Showcase
12th Dec 20167:00 amRNSBusiness Update
7th Nov 20167:10 amRNSAppointment of Chief Financial Officer
3rd Nov 20167:00 amRNSPositive Phase 1 interaction study with BCT-197
5th Oct 20167:00 amRNSDirectorate Change
16th Sep 20167:00 amRNSHalf-year Report
9th Aug 20164:04 pmRNSNotice of Results
18th Jul 20161:25 pmRNSResult of AGM
30th Jun 20167:00 amRNSBPS-804 granted EU orphan drug status
24th Jun 201612:47 pmRNSNotice of AGM
9th Jun 20161:17 pmRNSDirector/PDMR Shareholding
9th Jun 20168:01 amRNSFirst Day of Dealings on AIM
10th Nov 20086:21 pmRNSFurther re financial position
4th Nov 20083:01 pmRNSStatement re suspension
4th Nov 20083:00 pmRNSSuspension
23rd Oct 20084:35 pmRNSHolding(s) in Company
23rd Oct 20082:25 pmRNSAGM Statement
2nd Oct 20083:14 pmRNSHolding(s) in Company
23rd Sep 200810:02 amRNSNotice of AGM
1st Sep 200810:06 amRNSHolding(s) in Company
29th Aug 20083:20 pmRNSResult of GM and Interim Mana
26th Aug 200810:13 amRNSHolding(s) in Company
19th Aug 20082:22 pmRNSHolding(s) in Company
14th Aug 20084:23 pmRNSHolding(s) in Company
13th Aug 200811:00 amRNSDirectorate Change
8th Aug 200811:14 amRNSHolding(s) in Company
8th Aug 200811:03 amRNSHolding(s) in Company
7th Aug 20084:46 pmRNSHolding(s) in Company
6th Aug 20084:41 pmRNSSecond Price Monitoring Extn
6th Aug 20084:36 pmRNSPrice Monitoring Extension
6th Aug 20083:17 pmRNSDirector/PDMR Shareholding
6th Aug 20087:08 amRNSFundraising and New Board App
6th Aug 20087:05 amRNSNew Joint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.